We constructed an oncolytic adenoviral vector Ad.HE1HCD3, in which the adenoviral E1A promoter was replaced by a human tyrosinase enhancer (HTE)/promoter. The RGD-4C peptide was inserted into the HI loop of the fiber knob domain to increase the transduction efficiency of this vector for tumor cell lines. We also inserted the prodrug activating cytosine deaminase gene driven by the HTE/promoter into the E3 region of the Ad.HE1HCD3 vector. The in vitro cytotoxic effect of the Ad.HE1HCD3 vector with 5-fluorocytosine (5-FC) was greater than that of a wild-type adenovirus or that of the Ad.HE1HCD3 vector alone in tyrosinasepositive melanoma cell lines at low multiplicity of infection. Intratumoral injection of low doses of the Ad.HE1HCD3 vector into xenotransplanted human melanoma cell lines followed by the intraperitoneal injection of 5-FC led to a greater degree of tumor regression in vivo than did the intratumoral injection of the same dose of the Ad.HE1HCD3 vector alone. This oncolytic vector with a melanoma-specific prodrug activation therapeutic transcription unit and a RGD targeted fiber protein offers a potent therapeutic combination for the gene therapy of melanoma.
Introduction
Malignant melanoma is a highly aggressive tumor, which is the most rapidly growing cancer in incidence in the United States. 1 Although surgical removal of melanoma at an early stage is curative, once the tumor has disseminated, it is highly aggressive and very difficult to cure. Therefore, novel therapeutic approaches are needed.
Adenoviral vectors have been applied to the gene therapy of a variety of cancers because the viral particles are very stable, the viral genome can accommodate relatively large foreign genes, and these vectors have high infection efficiency for quiescent as well as dividing cells. 2 Conditionally replication-competent adenoviral (CRAD) vectors have shown promising results in clinical trials. 3 These vectors can be produced either by the introduction of loss of function mutations into viral replication genes, which can be complemented by helper functions presented in tumor cells, 4, 5 or by using tumor-specific promoters driving critical viral genes, such as the E1A gene of the adenovirus, so that they can be expressed only in tumor cells. 6 The infection efficiency of adenoviral vectors to tumor cells can also be improved by insertion of the RGD-4C motif into the HI loop of the adenovirus fiber domain, thus allowing the virus to use the a v b 3 integrin as an alternative receptor. Such modification has increased the transduction efficiency of adenoviral vector in CARdeficient tumor cells. 7 Gene therapy vectors have also been used as delivery vehicles for prodrug activation transcription units for the treatment of some forms of cancer. 8, 9 The introduction of suicide genes and tumor-specific replication competency into vectors produces a therapeutic tumor-suppressive effect, which is greater than vectors with tumor specific replication competency alone or with suicide gene alone. [10] [11] [12] In the studies reported in the present paper, we describe a new CRAD vector Ad.HE1HCD3 in which the adenoviral E1A promoter was replaced by two human tyrosinase enhancers (HTEs) and one human tyrosinase promoter. The RGD-4C peptide was also inserted into the HI loop of the fiber of the vector. The vector also contains a cytosine deaminase (CD) prodrug activation transcription unit driven by the HTE/promoter in the E3 region. We demonstrate that the infection of cells with the Ad.HE1HCD3 vector results in melanoma-specific expression of E1A protein, thereby generating a melanoma specific replication and cytolytic effect. At low multiplicity of infection (MOI), the in vitro cytotoxic effect of the Ad.HE1HCD3 vector plus 5-fluorocytosine (5-FC) was higher than that of wild-type adenovirus, than that of the Ad.HE1HCD3 vector alone, or than that of a replication-deficient adenoviral vector which contains the CD gene driven by cytomegalovirus (CMV) promoter in a tyrosinase-positive melanoma cell line. The Ad. HE1HCD3 vector plus 5-FC shows a greater antitumoral effect at low MOI than the Ad.HE1HCD3 vector alone in human melanoma xenografts models as well.
Materials and methods

Cell lines
The human embryonic kidney 293 cell, human melanoma cell lines SK-Mel-28, MeWo and the HeLa human cervical carcinoma cell line were purchased from American Type Culture Collection (ATCC, Manassas, VA). The YUSAC2 human melanoma cell line was kindly provided by Dr Ruth Halaban at Yale University (New Haven, CT). Normal human mammary epithelial cells (HMEC) were purchased from Clonetics (Walkersville, MD). Cells were grown at 371C in a humidified atmosphere of 5% CO 2 .
Reporter plasmids
The human tyrosinase promoter (HTP) (À209 to þ 51 bp relative to the human tyrosinase transcription start site) and the HTE (À2014 to À1810 bp relative to the human tyrosinase transcription start site) were obtained by polymerase chain reaction (PCR) from Ad.Tyr-E1A vector. 13 The CMV promoter/enhancer was obtained by PCR from pShuttle-CMV plasmid.
14 pGL3-HTE2TP plasmid was generated by inserting a KpnI/XhoI fragment containing two HTE and one HTP constructs into the KpnI/XhoI restriction site of the pGL3-basic vector (Promega, Madison, WI) upstream of the luciferase gene. pGL3-HTE4TP plasmid was generated by inserting a KpnI/XhoI fragment containing four HTE and one HTP constructs into the pGL3-basic vector upstream of the luciferase gene. pGL3-CMV plasmid was generated by inserting a KpnI/XhoI fragment of CMV promoter/ enhancer into the pGL3-basic vector upstream of the luciferase gene.
The reporter plasmids pTrack-HTE2TPLuc and pTrack-HTE4TPLuc were generated by inserting the KpnI/SalI fragment from pGL3-HTE2TP or pGL3-HTE4TP into the KpnI/SalI restriction site of the pTrack vector 21 , respectively. The pTrack-Luc plasmid that was constructed by inserting a KpnI/SalI fragment from pGL3-basic vector into the pTrack vector serves as a negative control. The pTrack-CMVLuc plasmid that was constructed by inserting a KpnI/SalI fragment from pGL3-CMVLuc vector into the pTrack vector serves as a positive control.
Transfection and analysis of reporter gene activity Plasmids used for transfection experiments were purified using Qiagen HiSpeed Plasmid Midi kit (Qiagen, Valencia, CA). The SK-Mel-28 human melanoma cell line and the HeLa human cervical carcinoma cell line were grown in 12-well plates to subconfluency and were transfected by 4 ml Lipofectamine 2000 (Invitrogen, Carlsbad, CA) with 1.2 mg of reporter plasmid. Cells were collected 24 h post-transfection. Green fluorescent protein (GFP)-positive cell numbers were counted by flow cytometry. Luciferase activity was determined by luciferase assay kit (Promega) and the protein concentration was determined by using a Bio-Rad DC protein assay kit (Bio-Rad, Hercules, CA).
Recombinant adenoviral vectors
Plasmid pAd(RGD) 20 was used as the template for the PCR reaction. Primer 1: 5 0 -GGACTAGTTTCGCG CCCTTTCTC-3 0 and primer 2: 5 0 -GTCGACGCGTC GCGCCGTTTAAACCTTCATGTAATCCAA-3 0 were used to amplify the 1050 bp PCR1 fragment (nt 27080-28130 of the Ad5 genome); primer 3: 5 0 -GTTTAAA CGGCGCGACGCGTCGACTCTTATTCCCTTTAAC 3 0 and primer 4: 5 0 GGAATTCCATATGGATACAC GGGGTTG 3 0 were used to amplify the 272 bp PCR2 fragment (nt 30821-31093 of the Ad5 genome). PCR1 and PCR2 were joined by PCR reaction by using primer 1 and primer 4. The 1320 kb band generated contained part of the Ad5 sequence from the SpeI site (nt 27080) to the NdeI site (nt 31093) with the deletion of E3 region (nt 28130-30820 of the Ad5 genome), and a short oligo insertion (in boldface) which created PmeI site and SalI site from nt 28130 of the Ad5 genome to nt 30820 of the Ad5 genome). Plasmid pAd.Pmel/SalI(R) was generated by replacing the SpeI/NdeI fragment of the plasmid pAd(RGD) (nt 27080-31093) by this 1320 kb PCR fragment.
The HTE2TPLuc DNA fragment, which contained the luciferase gene driven by HTE2TP and followed by SV40 poly(A), was inserted into the pAd.Pmel/SalI(R) plasmid by PmeI and SalI. The plasmid generated was named pAd.HLuc3. The HTE2TPCD DNA fragment which contained the Eshcherechia coli CD gene driven by HTE2TP and followed by SV40 poly(A) sequence was inserted into the pAd.PmeI/SalI(R) plasmid by PmeI and SalI. The plasmid generated was named pAd.HCD3. pAd.HLuc3 plasmid and pAd.HCD3 plasmid contained the same sequence as pAdeasy-1 plasmid 21 , except for two modifications. First, an additional RGD-4C sequence was inserted into the HI loop. Second, a luciferase gene or CD gene, which was driven by two HTEs and one human tyrosinase promoter (HTE2TP) and followed by SV40 poly(A), were inserted into the E3 region.
The pShuttleHLuc plasmid was constructed by inserting the HTE2TPLuc fragment into the pShuttle plasmid. 14 The pShuttleHCD plasmid was constructed by inserting the HTE2TPCD fragment into the pShuttle plasmid. DNA fragment HTE2TPCDIRESLuc, which contained the CD gene and the luciferase gene linked by an IRES sequence, driven by the HTE2TP and followed by SV40 poly(A), was inserted into the pShuttle plasmid. The generated plasmid was named pShuttleHCDIRESLuc. The HTE2TPE1 DNA fragment, which contained E1 gene of Ad5 (nt 541-5791) driven by HTE2TP, was inserted into the pShuttle plasmid. The generated plasmid was named pShuttleHE. To avoid nonspecific gene expression induced by the Ad5 left hand ITR in the pShuttle plasmid, a synthetic poly(A) sequence obtained by PCR from pGL3-basic plasmid (Promega) was inserted right upstream of the enhancer/promoters to all of the shuttle plasmids.
The Ad.HLuc1HCD3, Ad.HCDIRESLuc1HCD3 and Ad.HE1HCD3 vectors were obtained by homologous recombination between the pShuttleHLuc, pShuttleHCDIRESLuc or pShuttleHE and the pAd.HCD3 plasmid, followed by PacI digestion and transfection into 293 cells. The Ad.HCD1HLuc3 and Ad.HE1HLuc3 vectors were obtained by homologous recombination between the pShuttleHCD, or pShuttleHE and the pAd.HLuc3 plasmid, followed by PacI digestion and transfection into 293 cells. The Ad.HLuc(RGD) vector was obtained by homologous recombination between the pShuttleHLuc and pAd.(RGD) plasmid, followed digestion and transfection into 293 cells. The Ad.CMVLuc(RGD) and Ad.CMV-CD(RGD) vectors were constructed as described previously. 13 Human wild-type adenovirus 5 was purchased from ATCC (Manassas).
All the vectors were amplified in 293 cells and purified by CsCl 2 gradient ultracentrifugation. The titer of different vectors was tested by BD Adeno-Xt Rapid Titer Kit (BD Biosciences, Palo Alto, CA). The viral DNA was isolated from purified stocks and PCR was used for detecting wild-type virus according to methods previously described. 13 Ad-mediated gene transfer assay in vitro The Ad.CMV-Luc(RGD), Ad.HLuc1HCD3, Ad.-HCDIRESLuc1HCD3, Ad.HCD1HLuc3 and Ad.HE1H-Luc3 vectors were used to infect cell lines at MOI 1 or MOI 10. Cells were washed with phosphate-buffered saline (PBS) 48 h later. Luciferase activity was analyzed as before. 13 The protein concentration of the cell lysates was determined using a Bio-Rad DC protein assay kit (BioRad) to normalize the value of the relative light units (RLUs) by the protein concentration for each sample.
Western blot SK-Mel-28 and HeLa cells were plated on six-well plates and infected by the wild-type Ad5, Ad.HE1HCD3 or Ad.HLuc1HCD3 at MOI 10. Forty eight hours later, cells were harvested and immunoblotting was carried out to determine cellular E1A and human b-actin expression levels following the method described previously. 13 Antibody binding was visualized by enhanced chemiluminescence (Amersham Life Sciences Inc., Arlington Heights, IL).
Adenoviral vectors progeny production assay SK-Mel-28 and HeLa cells grown as monolayers in 12-well plates were infected with wild-type Ad5, the Ad.HLuc1HCD3 vector or the Ad.HE1HCD3 vector, respectively at MOI 1. Cells were treated with 0.5 mM 5-FC immediately (at day 0), 24 h later (at day 1), 48 h later (at day 2) or never treated with 5-FC. At day 7, the cell-free supernatant medium was collected. The titer of vectors in the supernatant medium was then determined by using the BD quick titer kit on 293 cells. 
Animal experiments
We evaluated the antitumor effects of the Ad.HE1HCD3 and the Ad.HLuc1HCD3 vectors in a human xenograft model using SK-Mel-28 human melanoma cell line. 1 Â 10 6 SK-Mel-28 cells were injected subcutaneously into 5-to 6-week-old severe combined immunodeficient (SCID) mice (Harlan Sprague Dawley Company, Indianapolis, IN). Tumor nodules were allowed to grow subcutaneously to approximately 70 mm 3 in size. The mice were randomly divided into three groups, the Ad.HLuc1HCD3 or the Ad.HE1HCD3 vectors (2 Â 10 7 ifu in both cases) were injected intratumorally into eight mice in a total volume of 50 ml for each treatment group, and with PBS for the control group (four mice). Forty eight hours after vector injection, 500 mg/kg of 5-FC was injected into the peritoneal cavity each day for 7 days (four mice in each treatment group). The tumor size was measured every 5 days and the tumor volume was calculated according to the formula: tumor volume ¼ length Â width 2 /2. In a separate experiment, mice containing SK-Mel-28 tumors were randomly divided into two groups, 1 Â 10 6 ifu of the Ad.HLuc1HCD3 or the Ad.HE1HCD3 vectors were injected intratumorally into each group (four mice/group for the Ad.HLuc1HCD3 vector and eight mice/group for the Ad.HE1HCD3 vector). Forty eight hours after vector injection, 500 mg/kg of 5-FC was injected introperitoneally each day for 7 days in the Ad.HLuc1HCD3 group and four mice in the Ad. HE1HCD3 group. The tumor size was measured according to the method mentioned above.
Results
Characterization of human tyrosinase enhancer/ promoter constructs
We first tested the transcriptional activity and specificity of different HTE/promoter constructs. Four reporter plasmids, pTrack-HTE2TPLuc, pTrack-HTE4TPLuc, pTrack-Luc and pTrack-CMVLuc were constructed for this purpose and the structures of these plasmids are shown in Figure 1 . To normalize the level of luciferase gene expression for different transfection efficiencies, the GFP-expression cassette was included in all of the reporter plasmids as an internal control.
Each of these reporter plasmids was transfected into the SK-Mel-28 human melanoma cell line and the HeLa human cervical cancer cell line. Luciferase activity was expressed as RLUs normalized to the protein concentration, and normalized to the number of GFP-positive cells. The results were presented as the ratio of luciferase activity generated by either the pTrack-CMVLuc plasmid (positive control) transfected cell line, or by the pTrackLuc plasmid (negative control) transfected cell line, to the luciferase activity generated by the pTrack-HTE2TPLuc plasmid transfected cell line, or to the luciferase activity generated by the pTrack-HTE4TPLuc plasmid transfected cell line (see Table 1 ).
The HTE2TP which contains two HTEs and one HTP generated a 31-fold-induced luciferase activity above that generated by the negative control pTrack-Luc plasmid in the SK-Mel-28 human melanoma cell line. In contrast, the luciferase activity generated by the HTE2TP plasmid in the HeLa human cervical cancer cell line is the same as negative control (Table 1) . The luciferase activity generated by the pTrack-HTE2TPLuc plasmid was lower by 14-fold in SK-Mel-28 cell line compared with the pTrackCMVLuc-positive control plasmid, whereas in HeLa cell line, it was 805-fold lower as compared with the pTrackCMVLuc-positive control plasmid. These results indicated that the HTE2TP construct induced specific expression of transgenes in tyrosinase-positive human melanoma cell line.
The combination of four HTEs linked to one HTP element in the pTrack-HTE4TPLuc plasmid did not increase the transcriptional activity in tyrosinase positive human melanoma cell line above that seen with the HTE2TP construct ( Table 1) . A similar expression pattern of transcriptional activation was observed when these four reporter plasmids were transfected into the MeWo human melanoma cell line (data not shown). Thus, we decided to use the HTE2TP transcriptional regulatory element in adenoviral vectors which we were constructing for melanoma gene therapy.
Construction of adenoviral vectors
If two therapeutic genes linked by an IRES sequence is placed under the control of one tumor-specific promoter, the expression level of the downstream gene on the 3 0 end of the IRES is usually weaker than the expression level of the upstream gene. Therefore, putting two therapeutic genes under the control of the same tumor-specific promoter in two separate sites in the adenoviral vector may increase the expression level of these therapeutic genes, and may increase the therapeutic effect thereby generated. Six adenoviral vectors with reporter transcription units were constructed to test this hypothesis. The Ad.HLuc1HCD3 vector contained the HTE2TP-Luciferase/poly(A) expression cassette (HTE2TPLuc) in the E1 region, and the HTE2TPCD/poly(A) expression cassette (HTE2TPCD) in the E3 region. The Ad.HCD1HLuc3 vector contained the HTE2TPCD in the E1 region and the HTE2TPLuc in the E3 region.
The HTE2TP-CDIRESLuciferase/poly(A) expression cassette (HTE2TPCDIRESLuc) was placed in the E1 region of the Ad.HCDIRESLuc1HCD3 vector which also contained the HTE2TPCD cassette in the E3 region. The Ad.HLuc(RGD) vector only contained the HTE2TPLuc in the E1 region. The Ad.CMV-Luc(RGD) vector served as a positive control. 13 These five reporter vectors are all replication-deficient vectors. The Ad.HE1HLuc3 vector is a CRAD vector which contains the HTE2TPE1 in the E1 region, and the HTE2TPLuc in the E3 region. The Ad.HE1HCD3 vector is a CRAD vector which contains the HTE2TPE1 in the E1 region, and the HTE2TPCD in the E3 region. The RGD-4C ligand was inserted into the HI loop of all of the vectors. A synthetic poly(A) sequence was inserted downstream of the left hand ITR to avoid nonspecific gene expression induced by the ITR in six of the seven vectors. The structural organization of each of these vectors is shown in Figure 2 The SK-Mel-28 human melanoma cell line and the HeLa human cervical cancer cell line were transiently transfected with different human tyrosinase enhancer/promoter constructs. The results were presented as the ratio of luciferase activity to positive control (pTrack-CMVLuc) or negative control (pTrackLuc). The number represents the mean7s.d. of two independent experiments.
Oncolytic adenoviral vector carrying cytosine deaminase gene Y Liu and A Deisseroth wide-type virus or replication-competent vector arising from recombination between the helper function cassettes in the producer cell lines and the vectors was confirmed by PCR (data not shown).
In vitro luciferase expression Cell lines were infected by different reporter vectors at MOI 1 or MOI 10. Luciferase activity was measured 48 h after infection. The results are shown in Figure 3 and Table 2 . Infection of the SK-Mel-28, YUSAC2 and MeWo human melanoma cell lines by the Ad.-HLuc1HCD3 vector resulted in relatively high levels of luciferase expression which is 12, 9 and 5%, respectively, of the luciferase level generated by the Ad.CMVLuc(RGD) vector in the same cell lines at MOI 1. In contrast, only background levels of luciferase (0.5, 0.06 and 0.02%, respectively) were seen in non-melanoma cell lines infected by the Ad.HLuc1HCD3 vector, when expressed as a percentage of the luciferase level generated by the Ad.CMV-Luc(RGD) vector in the HeLa human cervical cancer cell line, MCF-7 human breast cancer cell line, and in the normal human mammary epithelial cell line HMEC (see Table 2 ). Inserting two transcription units that contained two different transgenes induced by the same tumor-specific promoter into the E1 and the E3 region of one adenoviral vector did not interfere with the gene expression of each transcription unit, because the luciferase level in all of the tested cell lines generated by the Ad.HLuc(RGD) vector was no higher than the luciferase level generated by the Ad.HLuc1HCD3 vector in the same cell lines at the MOI 1 (data not shown).
The Ad.HLuc1HCD3 vector and the Ad.HCD1HLuc3 vector gave similar expression levels of luciferase in most cell lines tested at MOI 1, indicating that the insertion of a tumor-specific promoter/transgene cassette into the E3 region of an adenoviral vector did not change the expression level of the transgene compared to that generated by an adenoviral vector containing the same expression cassette in the E1 region. Moreover, at MOI 1, the Ad.HCD1HLuc3 vector has the same specific expression pattern as the Ad.HLuc1HCD3 vector. This suggested that the placement of a tumor-specific promoter into the E3 region still confers enhancer/promoter specific expression of the transcription unit at low MOI (see Figure 3 and Table 2 ).
However, at MOI 10, the Ad.HCD1HLuc3 vector gave a higher expression level of luciferase than did the Ad.HLuc1HCD3 vector in non-melanoma cell lines. At MOI 10, the luciferase level generated by the Ad. HCD1HLuc3 vector higher by 2.5-fold in the HeLa cell line, 5-fold in the MCF-7 cell line and 2.3-fold in the HMEC cell line, respectively, than seen in the same cell lines exposed to the Ad.HLuc1HCD3 vector. These results indicate that the placement of a tumor-specific promoter in the E3 region of adenoviral vector may decrease the specificity of the promoter compared with the placement of the same promoter in the E1 region of the adenoviral vector at relatively high MOI.
Infection of cell lines with the Ad.HCDIRESLuc1HCD3 vector gave much lower levels of luciferase Figure 3 and Table 2 ).
These results suggest that we should introduce the two therapeutic transcription units into separate sites in each vector (e.g., the E1 region or the E3 region) to obtain high expression level of therapeutic genes. We then created a replication competent adenoviral vector Ad.HE1HLuc3 in which the E1A promoter was replaced by the HTE2TP element and the HTE2TPLuc cassette was inserted into the E3 region. At the same MOI, the luciferase expression levels yielded by this vector was higher than that seen with all of the replication-incompetent vectors tested in the human melanoma cell lines, even higher than the luciferase levels seen with cell lines infected by the Ad.CMV-Luc(RGD) vector. At MOI 1, the luciferase levels generated by the Ad.HE1HLuc3 vector in the SK-Mel-28, YUSAC2 and MeWo cell lines were 17.2-, 83.7-and 137-fold higher, respectively, than those generated by the Ad. HCD1HLuc3 vector in the same cell lines ( Figure 3 and Table 2 ).
In addition, the luciferase expression levels generated by the Ad.HE1HLuc3 vector increased only slightly more in the tyrosinase negative HeLa, MCF-7 and HMEC nonmelanoma cell lines tested (six-, 2.4-and 1.7-fold, respectively), than seen when the Ad.HCD1HLuc3 vector was used to infect the same cell lines at MOI 1. These results indicate that the Ad.HE1HLuc3 vector selectively replicated in melanoma cell lines and also that the expression level of the luciferase gene in the E3 region was increased in vector infected melanoma cell lines compared with the same cell lines infected with the replication-deficient vectors.
Based on these results, we decided to construct the Ad.HE1HCD3 vector as a therapeutic vector. The E1A promoter was replaced by the HTE2TP in the Ad. HE1HCD3 vector to generate tumor-specific vector replication. The HTE2TPCD expression cassette was inserted into the E3 region of the Ad.HE1HCD3 vector to obtain high expression levels of the CD prodrug activation gene. Finally, the RGD-4C peptide was introduced into the HI loop of the fiber of the Ad.HE1HCD3 vector as well. The structure of this therapeutic vector is shown in Figure 2 .
Specific E1A expression in the SK-Mel-28 melanoma cell line exposed to the Ad.HE1HCD3 vector The SK-Mel-28 human melanoma cell line and the HeLa human cervical cancer cell line were infected with the wild-type adenovirus (Ad5), the Ad.HE1HCD3 vector or the Ad.HLuc1HCD3 vector at MOI 10. After 48 h of incubation, the expression of E1A protein was tested by Western blotting. The results, which are shown in Figure 4 , show similar E1A expression levels in both cell lines infected by the Ad5. Although the E1A protein level in the SK-Mel-28 melanoma cell line infected by the Ad.HE1HCD3 vector was similar to that seen with infection with Ad5, there was no detectable E1A expression in the HeLa cell line infected with the Ad.HE1HCD3 vector (signal similar to non-infected control). There was no detectable E1A expression in either of the two cell lines (SK-Mel-28 and HeLa) infected with the Ad.HLuc1HCD3 vector. These results confirmed that the Ad.HE1HCD3 vector induced melanoma-specific E1A expression.
Level of progeny vector released from the Ad.HE1HCD3 vector infected SK-Mel-28 melanoma cells as compared to HeLa cells
To determine the replicative potential of the Ad. HE1HCD3 vector, SK-Mel-28 and HeLa cells were infected by the Ad5, the Ad.HE1HCD3 vector, or by the Ad.HLuc1HCD3 vector. The titer of the released viral particles generated after 7 days was determined using the BD Adeno-X Rapid Titer Kit on 293 cells. No evidence of infectious vector particles was obtained for either of the cell lines infected with the Ad.HLuc1HCD3 vector as expected. The supernatants from the SK-Mel-28 cell line exposed to the Ad5 and the Ad.HE1HCD3 vector gave similar titers of progeny viruses (see Figure 5a) . The supernatants from the HeLa cell line infected by the Ad.HE1HCD3 vector produced levels of progeny viruses 9.8 Â 10 6 fold lower than that seen when HeLa cells were infected with the Ad5 virus (Figure 5a) . These results indicate a melanoma selective replication of the Ad.HE1HCD3 vector.
We also tested whether the CD gene in combination with 5-FC affects the levels of replication of the Ad.HE1HCD3 vector as measured by progeny virus produced. SK-Mel-28 cells were exposed to the Ad5 virus or the Ad.HE1HCD3 vector at MOI 1. Infected test cells were either not treated with 5-FC (À), or treated with 0.5 mM 5-FC immediately (day 0), 24 h later (day 1) or 48 h later (day 2). As shown in Figure 5b , there was no effect of the addition of 5-FC to the medium in which cells exposed to the Ad5 virus were cultured. Addition of 5-FC to the cultures of the SK-Mel-28 cells infected by the Ad.HE1HCD3 vector decrease the viral titer in the supernatant medium by 86-fold, 21-fold or 6-fold when the 5-FC was added at 0, 1 or 2 days after infection as compared to cultures to which 5-FC was not added. Addition of 5-FC to cultures of HeLa cells exposed to the Ad.HE1HCD3 vector did not change the low level of viral particles produced in that cell line (data not shown). These results indicated that 5-FC can decrease the level of progeny particles produced by the SK-Mel-28 melanoma cell line following exposure to the Ad.HE1HCD3 vector, and that the inhibition by 5-FC is CD gene-dependent.
In vitro cytotoxicity of the Ad.HE1HCD3 and the Ad.HLuc1HCD3 vectors to the SK-Mel-28 melanoma cell line and to the HeLa cell line To test the relative contribution of E1A versus the CD genes to the in vitro cytotoxic effect of the Ad.HLuc1HCD3 and the Ad.HE1HCD3 vectors, we exposed the SK-Mel-28 and HeLa cell lines to the Ad5 virus, to the Ad.HLuc1HCD3 or to the Ad.HE1HCD3 vectors, or to the Ad.CMV-CD(RGD) vector at MOI 1 or MOI 10, respectively. Levels of cytotoxicity were measured by MTS assay, which reflects the number of living cells at a specific time after infection relative to the uninfected control culture. The results are shown in Table 3 .
As expected, exposure of the SK-Mel-28 or HeLa cell lines to the Ad5 virus or to the Ad.CMV-CD(RGD) vector in cultures supplemented with 5-FC induced levels of cell killing which was identical for both cell lines. The level of cytotoxic effect increased as the MOI of vectors was increased. In the absence or presence of 5-FC, the Ad.HE1HCD3 vector produced higher levels of cytotoxicity in the SK-Mel-28 melanoma cell line than did the same vector in the HeLa cervical cancer cells at MOI 1 or MOI 10. At MOI 10, a measurable but low cytotoxic effect was observed in HeLa cells infected with the Ad.HE1HCD3 vector ( Table 3) .
Infection of the SK-Mel-28 cells with the Ad.HLuc1HCD3 vector had no significant cytotoxic effect at either MOI without 5-FC. Moreover, the Ad.HLuc1HCD3 vector in the presence of 5-FC produced no significant cytotoxic effect at MOI 1, indicating that even in the melanoma cells, the expression level of CD gene is not high enough at MOI 1 to cause cell death. At MOI 10, significant cytotoxic effect was seen in the SK-Mel-28 melanoma cells (44% cell alive) exposed to the Ad.HLuc1HCD3 vector in the presence of 5-FC, whereas only very small cytotoxic effect was seen in HeLa cells (86% cell alive) following exposure to the Ad.HLuc1HCD3 vector in the presence of 5-FC (Table 3 ). When we decreased the number of the vector particles injected intratumorally to 1 Â 10 6 ifu for the Ad.-HLuc1HCD3 vector or the Ad.HE1HCD3 vector, the in vivo suppression of tumor growth in Ad.HE1HCD3 vector injected SCID mice not given with 5-FC is greater than that generated by intratumoral injection of the Ad.HLuc1HCD3 vector into SCID mice also injected intraperitoneally with 5-FC (Po0.05). The intratumoral injection of the Ad.HE1HCD3 vector in SCID mice also injected with 5-FC produced the greatest antitumor effect among three therapeutic groups (Figure 6b ).
Discussion
In our experiments, we replaced the adenoviral E1A promoter by a 260 bp fragment of the human tyrosinase promoter fused to a dimer of two contiguous 200 bp HTEs, which has been shown to mediate specific transcription activity in melanoma cells. 15 We constructed pTrack-HTE2TPLuc and pTrack-HTE4TPLuc reporter plasmids, in which the luciferase gene was regulated by two or four copies of the HTEs fused to a 260 bp fragment of the human tyrosinase promoter (HTE2TP or HTE4TP, respectively). Both of the reporter vectors induced specific expression of the luciferase gene in melanoma cell lines. In contrast to a previous report, 16 there was no observed increase of reporter gene transcriptional activity between the pTrack-HTE2TPLuc reporter plasmid and the pTrack-HTE4TPLuc reporter plasmid (Table 1) . We therefore replaced the E1A gene promoter with the HTE2TP for the reporter and therapeutic CRAD vectors construction for melanoma. When two different transgenes driven by one promoter were linked by the IRES sequence, the expression level of the downstream gene on the 3 0 end of the IRES is usually weaker than the expression level of the upstream gene. To verify this and to test the specificity and activity of the tumor-specific promoter in the E3 region of the adenoviral vectors, we constructed reporter vectors Ad.HLuc1HCD3, Ad.HCD1HLuc3 and Ad.HCDIRESLuc1HCD3. A panel of cell lines was infected by these vectors and luciferase activity was measured to indicate the expression levels of transgene. The HTE2TP induced similar expression levels of luciferase at low MOI whether it was placed in the E1 region or in the E3 region (see Table 2 and Figure 3) . Moreover, the HTE2TP construct maintains specificity at low MOI when it was placed in the E3 region of the adenoviral vector. Infection of cells with the Ad.HCDIRESLuc1HCD3 vector gave much lower luciferase expression levels than did infection of cells with the vector carrying the luciferase gene directly downstream of the HTE2TP in all the melanoma cells tested (Table 2 and Figure 3 ).
Our previous experiments had shown that a decrease in the expression level of E1A may result in decreased replicative ability of the vector, thereby decreasing the direct cytolytic effect of the vector. 17 The adenovirus E1A vector and is able to exert its antitumor effect on many different tumor types.
18 E1A-mediated bystander effect, such as inhibition of angiogenesis and induction of apoptosis, also results in tumor suppression. 19 Although previous reports had shown that low levels of E1A protein may be sufficient for the replication of adenovirus, 20 priority was given in the design of the vectors in this paper to produce high expression levels of both the E1A gene and the CD prodrug gene at a melanoma-specific manner in one CRAD vector.
We found no loss of specificity at low MOI resulting from the placement of the HTE2TP in the E3 region versus the E1 region. At high MOI, there is a decrease of specificity for the HTE2TP element in the E3 region versus the E1 region (Table 2 and Figure 3) . Therefore, we replaced the promoter of E1A by the HTE2TP construct in the E1 region, and placed the therapeutic transcription unit in the E3 region of the same vector. We predicted that such a vector would replicate specifically in melanoma cells, and that the replication of the vector would in turn increase the level of the protein production of the therapeutic gene in melanoma cells. We constructed the Ad.HE1HLuc3 vector to test this hypothesis. The luciferase activity generated by the Ad.HE1HLuc3 vector is higher than all of the replication-incompetent vectors in all of the human melanoma cell lines tested, but it remains low in non-melanoma cell lines (Table 2 and Figure 3) .
Our final CRAD therapeutic vector (Ad.HE1HCD3) contained the HET2TP element 5 0 to the E1A gene, and a HTE2TPCD therapeutic transcription unit in the E3 region. A RGD-4C peptide was inserted into the HI loop of the Ad.HE1HCD3 vector to increase the infection efficiency of the vector in melanoma tumor cells. We observed that all of the following were melanoma specific when the melanoma cells were exposed to the Ad.HE1HCD3 vector: E1A gene expression, vector replication and cytotoxicity effect (see Figures 4 and 5) .
The expression of the CD gene plus 5-FC can reduce the viral progeny yield of the Ad.HE1HCD3 vector from infected melanoma cells (Figure 5b ). This may be a reflection of the effect of the 5-FU produced on viral replication, as well as cytotoxicity in the cells producing the vector. Such a complex interaction between viral replication and the therapeutic effect of prodrug gene has been shown in previous reported work. 21 More work will be needed to optimize the interaction between direct cytotoxicity effect of 5-FU, and spread of the infection throughout a tumor owing to the release of infectious vector particles from infected cells.
At high MOI, there is no difference between the in vitro cytotoxic effect of the Ad.HE1HCD3 vector without 5-FC and the Ad.HE1HCD3 vector plus 5-FC in melanoma cells (see Table 3 ), which indicated that at a high multiplicities of the vector, the direct replicative cytolytic effect of the vector may be sufficient to kill most of the melanoma cells. However, it is not always possible to achieve such high multiplicities in an in vivo therapeutic setting. Therefore, the observed increase in in vitro cytotoxicity induced by the addition of 5-FC to the Ad.HE1HCD3 vector in melanoma cell lines at low MOI may represent an important advantage in the in vivo therapeutic setting.
When relatively high viral titers (2 Â 10 7 ifu) were used for intratumoral injection in vivo, both the Ad.HE1HCD3 vector without 5-FC and the Ad.HE1HCD3 vector plus 5-FC suppressed melanoma tumor growth with the antitumor effect of the Ad.HE1HCD3 vector being higher than that of the replication-deficient Ad.HLuc1HCD3 vector plus 5-FC (see Figure 6a) . At relatively lower vector doses (1 Â 10 6 ifu), the replication-deficient Ad. HLuc1HCD3 vector with 5-FC failed to suppress growth of vector injected subcutaneous melanoma nodules. The antitumor effect of the Ad.HE1HCD3 vector plus 5-FC is superior than that of the Ad.HE1HCD3 vector without 5-FC ( Figure 6b ). As intratumoral injection of high numbers of the CRAD vectors that may be required for efficacy may produce leakage into surrounding normal tissues and into the bloodstream, the presence of the melanoma-specific promoters and enhancers, the RGD targeting ligands, as well as melanoma-specific prodrug activation transcriptional units, may provide the safety necessary for these vectors to be useful clinically.
